Site search
2831 results for '' found
Re-Evaluation of the Corvia Atrial Shunt Device in a Precision Medicine Trial to Determine Efficacy in Mildly Reduced or Preserved EF Heart Failure (RESPONDER-HF) (NCT05425459)
Re-Evaluation of the Corvia Atrial Shunt Device in a Precision Medicine Trial to Determine Efficacy in Mildly Reduced or Preserved EF Heart Failure (RESPONDER-HF) (NCT05425459)
/
RESpiratory pathogen Point-Of-Care Testing in Emergency Departments (ACTRN12625000123448)
RESpiratory pathogen Point-Of-Care Testing in Emergency Departments (ACTRN12625000123448)
/
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomon
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomon
/
A multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled phase 3 study to evaluate the efficacy and safety of bendralizumab 100mg in patietns with moderate to v
A multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled phase 3 study to evaluate the efficacy and safety of bendralizumab 100mg in patietns with moderate to v
/
Randomized,Embedded,Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) (NCT02735707)
Randomized,Embedded,Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) (NCT02735707)
/
A prospective, double-blinded, randomised study comparing 16g automated full-core and side-notch biopsy needles for percutaneous renal biopsies in renal transplant patients (Trial Not Registered)
A prospective, double-blinded, randomised study comparing 16g automated full-core and side-notch biopsy needles for percutaneous renal biopsies in renal transplant patients (Trial Not Registered)
/
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previo
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previo
/
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB [REGN2810], ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA [CSCC] OR BASAL CELL CARCINOMA [BCC] (NCT03889912)
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB [REGN2810], ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA [CSCC] OR BASAL CELL CARCINOMA [BCC] (NCT03889912)
/
A First-In-Human (FIH) Phase 1/2 Study To Assess Safety, Tolerability, And Preliminary Anti-Tumor Activity Of REGN7945, An Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, In C
A First-In-Human (FIH) Phase 1/2 Study To Assess Safety, Tolerability, And Preliminary Anti-Tumor Activity Of REGN7945, An Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, In C
/
Reducing the frequency of outpatient review in people with cystic fibrosis on high-efficacy modulator therapy – a non-inferiority, randomised controlled trial (REFORM) (ACTRN12624000696594)
Reducing the frequency of outpatient review in people with cystic fibrosis on high-efficacy modulator therapy – a non-inferiority, randomised controlled trial (REFORM) (ACTRN12624000696594)
/